Filtered By:
Drug: Coumadin
Therapy: Dialysis
This page shows you your search results in order of relevance. This is page number 7.
Order by Relevance | Date
Total 159 results found since Jan 2013.
Treatment of atrial fibrillation with warfarin among older adults with end stage renal disease.
CONCLUSION: Despite the unclear benefit and increased bleeding risk of warfarin treatment in patients with ESRD, 1 in 8 older adults undergoing dialysis with incident AF in the US who had high risk of bleeding used warfarin. Changes to warfarin therapy due to discontinuation were common after initiation.
PMID: 28120282 [PubMed - as supplied by publisher]
Source: Journal of Nephrology - January 23, 2017 Category: Urology & Nephrology Authors: Tan J, Bae S, Segal JB, Zhu J, Segev DL, Alexander GC, McAdams-DeMarco M Tags: J Nephrol Source Type: research
Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients
It is unclear whether warfarin is protective or harmful in patients with ESRD and atrial fibrillation. This state of equipoise raises the question of whether alternative anticoagulants may have a therapeutic role. We aimed to determine apixaban pharmacokinetics at steady state in patients on hemodialysis. Seven patients received apixaban 2.5 mg twice daily for 8 days. Blood samples were collected before and after apixaban administration on days 1 and 8 (nondialysis days). Significant accumulation of the drug was observed between days 1 and 8 with the 2.5-mg dose. The area under the concentration-time curve from 0 to 24 hou...
Source: Journal of the American Society of Nephrology : JASN - June 30, 2017 Category: Urology & Nephrology Authors: Mavrakanas, T. A., Samer, C. F., Nessim, S. J., Frisch, G., Lipman, M. L. Tags: Clinical Research Source Type: research
‘Some doors are better left closed’: Using LAA occluders as an alternative to warfarin in very high-risk dialysed patients with atrial fibrillation
Since 2011, when the EMA approved the treatment with novel oral anticoagulants (NOACs) for primary prevention of cardio-embolic stroke in patients with atrial fibrillation (AF), a reasonable question repeatedly arose: “Will NOACs become the new standard of care in anticoagulation therapy?” [1]. While for many cathegories of patients the answer soon become positive [2], the sub-group of advanced chronic kidney disease (CKD) 5D stage (in dialysis) has never received a “yes” from either FDA or EMA (none of t hem allowing the use of NOACs in 5D CKD).
Source: International Journal of Cardiology - April 27, 2018 Category: Cardiology Authors: Alexandru Burlacu, Adrian Covic Tags: Editorial Source Type: research
Warfarin Use And the Risk Of Stroke, Bleeding, And Mortality In Older Adults On Dialysis With Incident Atrial Fibrillation
Nephrology,Volume 0, Issue ja, -Not available-.
Source: Nephrology - December 8, 2017 Category: Urology & Nephrology Authors: Jingwen
Tan
ScM, PhD
,
Sunjae
Bae
KMD, MPH
,
Jodi B.
Segal
MD, MPH
,
Junya
Zhu
PhD
,
G. Caleb
Alexander
MD, MS
,
Dorry L.
Segev
MD, PhD
,
Mara
McAdams ‐DeMarco
PhD Source Type: research
Demystifying the Benefits and Harms of Anticoagulation for Atrial Fibrillation in Chronic Kidney Disease.
This article aims to present a contemporary literature review of the benefits versus harms of anticoagulation in atrial fibrillation for patients with CKD stages 3, 4, 5, and 5 on dialysis. Although unanswered questions and areas of clinical equipoise remain, this piece serves to assist physicians in interpreting the complex body of literature and applying it to their clinical care.
PMID: 30593489 [PubMed - as supplied by publisher]
Source: Clinical Journal of the American Society of Nephrology : CJASN - December 28, 2018 Category: Urology & Nephrology Authors: Garlo KG, Steele DJR, Nigwekar SU, Chan KE Tags: Clin J Am Soc Nephrol Source Type: research
Warfarin in nonvalvular atrial fibrillation-Time for a change?
Abstract
Warfarin is the most commonly prescribed anticoagulant in hemodialysis (HD) patients with nonvalvular atrial fibrillation (NVAF). Recent trends show that Nephrologists are increasingly prescribing novel oral anticoagulants, despite the fact that no randomized clinical trials have been conducted in dialysis patients. Difficulties maintaining international normalized ratio in the therapeutic range, increased risk of intracranial hemorrhage and concerns regarding warfarin-induced vascular calcification and calciphylaxis may be responsible. Anticoagulation quality is poor in HD patients. A variety of factors ...
Source: Seminars in Dialysis - June 16, 2019 Category: Urology & Nephrology Authors: Reilly RF, Jain N Tags: Semin Dial Source Type: research
Systematic DOACs oral anticoagulation in patients with atrial fibrillation and chronic kidney disease: the nephrologist's perspective.
Abstract
Atrial fibrillation (AF) is highly prevalent among patients with chronic kidney disease (CKD), and also associated with unfavorable outcome. Anticoagulant therapy is the mainstep of management in such patients, aimed at reducing the high risk of systemic thromboembolism and especially of ischemic stroke, which is reportedly associated with increased mortality in CKD patients. Even though new direct oral anticoagulant agents (DOACs) proved to be effective in patients with non valvular chronic AF, and are therefore recommended by recent guidelines for their treatment, warfarin is currently used in more than...
Source: Journal of Nephrology - March 20, 2020 Category: Urology & Nephrology Authors: Ravera M, Bussalino E, Fusaro M, Di Lullo L, Aucella F, Paoletti E Tags: J Nephrol Source Type: research
End-Stage Renal Disease, Nonvalvular Atrial Fibrillation, and the Warfarin Dilemma
There are more than 660,000 Americans with kidney failure and nearly 470,000 on dialysis.1 Of these, estimates of nonvalvular atrial fibrillation (NVAF) approach 20%.2 Atrial fibrillation nearly doubles the anticipated mortality and increases the stroke risk by approximately six-fold in these patients. The intersection between end-stage renal disease (ESRD) and NVAF is complicated and not easily parsed. Atrial fibrillation likely increases the rate of progression to ESRD in patients with underlying chronic kidney disease (CKD).
Source: Mayo Clinic Proceedings - May 31, 2020 Category: Internal Medicine Authors: Robert D. McBane Tags: Editorial Source Type: research
Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis
ConclusionsDOACs did not provide benefit over warfarin regarding effectiveness and safety in AF patients undergoing dialysis. The use of OAC was not associated with a lower risk of IS/SE in ESRD AF patients when compared to those without OAC use.
Source: Cardiovascular Drugs and Therapy - November 19, 2020 Category: Cardiology Source Type: research
Effect of Rivaroxaban or Apixaban in Atrial Fibrillation Patients with Stage 4 –5 Chronic Kidney Disease or on Dialysis
ConclusionsCurrent evidence suggests that rivaroxaban or apixaban are safe and at least as effective as warfarin in patients with AF and stage 4 –5 CKD or on dialysis.
Source: Cardiovascular Drugs and Therapy - February 4, 2021 Category: Cardiology Source Type: research
A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease
CONCLUSION: Further studies are still required, some ongoing, in patients with advanced CKD (CrCl < 30 ml/min) to identify the safest and most effective treatment options for VTE and AF.PMID:36006608 | DOI:10.1007/s40620-022-01413-x
Source: Journal of Nephrology - August 25, 2022 Category: Urology & Nephrology Authors: Kathrine Parker John Hartemink Ananya Saha Roshni Mitra Penny Lewis Albert Power Satarupa Choudhuri Sandip Mitra Jecko Thachil Source Type: research
